ライフサイエンスコーパス: randomly assign @1 patients to

1 e screened for eligibility, 393 of whom were randomly assigned, 206 patients to abemaciclib plus abir

2 Between Aug 9, 2016, and Dec 7, 2018, we randomly assigned 288 patients to aIGB (n=187 [65%]) or

3 In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg dai

4 We randomly assigned 2000 patients to BIS-guided anesthesia

5 Using a 2-by-2 factorial design, we randomly assigned 452 patients to chemotherapy with or w

6 Between Dec 22, 2008, and May 26, 2011, we randomly assigned 221 patients to chlorambucil plus ofat

7 We randomly assigned 22 patients to conventional haemorrhoi

8 March 2014 and June 2018, 105 patients were randomly assigned (53 patients to CRS-A and 52 patients

9 Between Dec 23, 2009, and June 11, 2013, we randomly assigned 480 patients to dacomitinib and 240 pa

10 Between Oct 29, 2010, and Oct 4, 2012, we randomly assigned 225 patients to dapagliflozin and 224

11 etes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to a

12 7, 2013, and March 25, 2014, we enrolled and randomly assigned 365 patients to different treatment ar

13 Between Jan 7, 2004, and May 24, 2012, we randomly assigned 425 patients to each treatment group.

14 From 2004 through 2008, we randomly assigned 366 patients to either five weekly cyc

15 We randomly assigned 920 patients to either "invasive" mana

16 We randomly assigned eligible patients to either intraarter

17 4, 2010, and Dec 21, 2010, we recruited and randomly assigned 73 patients to elotuzumab (36 to 10 mg

18 b 7, 2013, and July 1, 2014, we enrolled and randomly assigned 42 patients to erlotinib treatment, 40

19 Between Feb 4, 2015, and July 12, 2016, we randomly assigned 294 patients to extrafine inhaled cort

20 Between Jan 1, 2014, and April 11, 2015, we randomly assigned 50 patients to group 1 (n=25) or group

21 etween June 26, 2017, and April 24, 2019, we randomly assigned 71 patients to group A and 285 to grou

22 We enrolled and randomly assigned 413 patients to groups, of whom 207 pa

23 We randomly assigned 807 patients to groups that received o

24 We randomly assigned 1623 patients to lenalidomide and dexa

25 We randomly assigned 251 patients to mitral-valve repair or

26 From April 13, 2011, to Sept 21, 2012, we randomly assigned 276 patients to montelukast (n=137) or

27 Between June 25, 2014, and June 15, 2015, we randomly assigned 444 patients to neoadjuvant treatment

28 , we screened 179 patients and enrolled 142, randomly assigning 95 patients to nivolumab plus ipilimu

29 etween June 13, 2008, and April 26, 2012, we randomly assigned 355 patients to ombrabulin plus cispla

30 tional Single Ventricle Reconstruction trial randomly assigned 555 patients to one or the other shunt

31 We randomly assigned 96 patients to one of the four study g

32 We randomly assigned the patients to one of four treatment

33 In a double-blind fashion, we randomly assigned 1133 patients to placebo and 1156 pati

34 We randomly assigned 22 patients to placebo or IL-1ra (1:1)

35 ath in Heart Failure Trial (SCD-HeFT), which randomly assigned 2521 patients to placebo, amiodarone,

36 We randomly assigned the patients to placebo, losartan (100

37 ratified randomization algorithm was used to randomly assign eligible patients to receive usual care,

38 We randomly assigned 101 patients to receive placebo (n=50)

39 We randomly assigned 1015 patients to receive doses of warf

40 Between Nov 24, 2015, and March 21, 2017, we randomly assigned 1032 patients to receive durvalumab (n

41 In this double-blind study, we randomly assigned 1088 patients to receive abiraterone a

42 11, 2017, and Feb 22, 2018, we enrolled and randomly assigned 114 patients to receive either epleren

43 Between Feb 22, 2013, and May 13, 2015, we randomly assigned 120 patients to receive methotrexate (

44 We randomly assigned 1206 patients to receive neoadjuvant t

45 Between Dec 3, 2007, and March 8, 2010, we randomly assigned 1290 patients to receive chemotherapy

46 We randomly assigned 135 patients to receive a central veno

47 tween March 23, 2012, and March 31, 2014, we randomly assigned 136 patients to receive brief guided p

48 We randomly assigned 138 patients to receive G-CSF (n=71) o

49 Between June 12, 2012, and June 24, 2013, we randomly assigned 140 patients to receive placebo (n=62)

50 e in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloro

51 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination th

52 In this double-blind, phase 3 study, we randomly assigned 1717 patients to receive either enzalu

53 Between Aug 20, 2012, and June 17, 2013, we randomly assigned 176 patients to receive subcutaneous r

54 etween June 14, 2010, and April 21, 2011, we randomly assigned 192 patients to receive axitinib, and

55 le for high-dose interferon alfa therapy, we randomly assigned 20 patients to receive the antidepress

56 Between July 1, 2011, and Nov 4, 2015, we randomly assigned 200 patients to receive standard treat

57 We randomly assigned 2013 patients to receive bare-metal, z

58 We randomly assigned 2254 patients to receive liraglutide (

59 Between Aug 10, 2010, and May 14, 2015, we randomly assigned 229 patients to receive placebo (n=114

60 Between March 26, 2013, and Aug 26, 2014, we randomly assigned 230 patients to receive ataluren (n=11

61 We randomly assigned 234 patients to receive standard chemo

62 ounger than 66 years of age at diagnosis, we randomly assigned 240 patients to receive rituximab main

63 In two separate trials, we randomly assigned 245 patients to receive in-center dail

64 Between July 9, 2012, and Feb 5, 2014, we randomly assigned 250 patients to receive either AAV1/SE

65 Between Oct 16, 2012, and Dec 13, 2014, we randomly assigned 252 patients to receive either artesun

66 cancer that was refractory to iodine-131, we randomly assigned 261 patients to receive lenvatinib (at

67 Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n

68 We randomly assigned 272 patients to receive nivolumab, at

69 We randomly assigned 29 patients to receive either metformi

70 Between Oct 29, 2014, and Aug 19, 2016, we randomly assigned 298 patients to receive at least one d

71 We randomly assigned 300 patients to receive 900 mug of sub

72 We randomly assigned 302 patients to receive induction chem

73 We randomly assigned 323 patients to receive three subcutan

74 In this open-label phase 3 study, we randomly assigned 3360 patients to receive standard adju

75 etween April 14, 2005, and April 1, 2009, we randomly assigned 350 patients to receive erlotinib and

76 We randomly assigned 40 patients to receive either an intra

77 We randomly assigned 42 patients to receive oral doses of s

78 etween April 20, 2009, and June 30, 2010, we randomly assigned 44 patients to receive selumetinib and

79 ntly diagnosed mild or moderate Covid-19, we randomly assigned 452 patients to receive a single intra

80 Between Oct 4, 2011, and Feb 22, 2014, we randomly assigned 452 patients to receive placebo (n=151

81 Between June 29, 2010, and Jan 17, 2013, we randomly assigned 470 patients to receive the brief psyc

82 Between Dec 6, 2005, and Dec 21, 2012, we randomly assigned 477 patients to receive either radioth

83 pairment 6 months or more after a stroke, we randomly assigned 49 patients to receive intensive robot

84 2013, and Nov 7, 2013, and Aug 26, 2014, we randomly assigned 50 patients to receive CBT plus standa

85 We randomly assigned 553 patients to receive imatinib and 5

86 In two consecutive overnight sessions, we randomly assigned 56 patients to receive treatment with

87 We randomly assigned 599 patients to receive once-weekly du

88 Between April 27, 2009, and Oct 31, 2009, we randomly assigned 60 patients to receive either medical

89 We randomly assigned 60 patients to receive vancomycin (n =

90 Between Nov 11, 2009, and Feb 2, 2011, we randomly assigned 633 patients to receive either necitum

91 Between Sept 4, 2014, and Oct 15, 2015, we randomly assigned 695 patients to receive exenatide plus

92 In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9

93 We randomly assigned 77 patients to receive a continuous in

94 Between April 3, 2017 and Aug 23, 2018, we randomly assigned 853 patients to receive secukinumab (n

95 Between Jan 3, 2013, and Sept 24, 2014, we randomly assigned 860 patients to receive solithromycin

96 Between Dec 9, 2010, and Sept 21, 2012, we randomly assigned 884 patients to receive dulaglutide 1.

97 5, 2012, and April 29, 2016, we enrolled and randomly assigned 977 patients to receive levofloxacin p

98 Between May 14, 2009, and May 9, 2013, we randomly assigned 98 patients to receive either eltrombo

99 We randomly assigned the patients to receive either ribocic

100 We randomly assigned the patients to receive peginterferon

101 We randomly assigned these patients to receive a total of 4

102 Three hundred twenty-six patients were randomly assigned; 163 patients to SC and 163 to LC.

103 ll patients received sevelamer carbonate, we randomly assigned 109 patients to sevelamer (n=55) or pl

104 tween April 12, 2011, and March 30, 2012, we randomly assigned 758 patients to smear microscopy (182

105 dian age 2.95 years (range 1.03-20.97), were randomly assigned-132 patients to standard and 130 patie

106 We randomly assigned 351 patients to surgery and postoperat

107 Between Dec 16, 1992, and May 22, 2001, we randomly assigned 900 patients to surgery with either a

108 terminated early after 131 patients had been randomly assigned (66 patients to the intervention group

109 From October 2009 through April 2012, we randomly assigned 103 patients to the hybrid-procedure g

110 Between June 29, 2010, and Sept 16, 2013, we randomly assigned 130 patients to the Organ Care System

111 Between Aug 13, 2009, and May 30, 2014, we randomly assigned 1313 patients to the control group (n=

112 We randomly assigned 162 patients to the salbutamol group a

113 Between Aug 24, 2010, and Nov 13, 2012, we randomly assigned 2103 patients to the tiotropium 5 mug

114 Between Feb 23, 2011, and March 29, 2013, we randomly assigned 252 patients to the pitavastatin (n=12

115 Between April 6, 2010, and Sept 21, 2012, we randomly assigned 329 patients to the brentuximab vedoti

116 We randomly assigned 35 patients to the MK-7 group (33 comp

117 In cohort 1, we randomly assigned 60 patients to the 12-week regimen (31

118 n and 31 with no ribavirin); in cohort 2, we randomly assigned 65 patients to the 12-week regimen (32

119 GS: Between Feb 3, 2011, and Dec 1, 2011, we randomly assigned 88 patients to the Trevo Retriever gro

120 The Bayesian adaptive trial randomly assigned more patients to the better-performing

121 One hundred eighty-two patients were randomly assigned-92 patients to the lenalidomide arm an

122 A total of 195 evaluable patients were randomly assigned: 99 patients to the LEN-EPO alfa cohor

123 3505 participants in the IVUS-ACS study were randomly assigned (1700 patients to ticagrelor plus aspi

124 ts assessed for eligibility, we concurrently randomly assigned 1581 patients to treatment (nivolumab

125 Between Nov 19, 2010, and Dec 12, 2014, we randomly assigned 1794 patients to treatment, of whom 17

126 Between Jan 10, 2017, and Feb 2, 2018, we randomly assigned 307 patients to treatment: 154 to isat

127 Between Sept 14, 2012, and June 16, 2015, we randomly assigned 313 patients to treatment groups (106

128 From March 17, 2010, to Jan 15, 2013, we randomly assigned 67 patients to treatment, with 45 pati

129 Between Sept 1, 2010, and April 22, 2013, we randomly assigned 7028 patients to treatment groups and

130 a double-blind, placebo-controlled study, we randomly assigned 77 patients to treatment with celecoxi

131 Between July 25, 2012, and Jan 12, 2016, we randomly assigned 878 patients to treatment: 294 to plac

132 We randomly assigned 301 patients to undergo either CABG al

133 We randomly assigned 50 patients to undergo on-pump coronar

134 ospective, controlled, multicenter trial, we randomly assigned 91 patients to undergo transmyocardial

135 We randomly assigned 75 patients to usual care and 227 pati

136 etween March 8, 2011, and April 30, 2013, we randomly assigned 206 patients to vascular-targeted phot